Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BEX101
- Development stage
- Phase 2
- Lead developer
- Chinese PLA General Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
BEX101 is an extracorporeal, autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy. It is designed to target and eliminate CD19-expressing malignant B cells. Developed by the Chinese PLA General Hospital, BEX101 is being evaluated in clinical trials for the treatment of patients with relapsed or refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL).
- Other names
- BEX101 injectionBEX-101 injectionBEX 101 injection
02
Targets
Beyond the preview
Go deeper on BEX101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BEX101.